[
  {
    "criterion": "Provides incorrect information about the CHA2DS2-VASc score and its application for stroke risk assessment in patients with atrial fibrillation and hypertension.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Does not mention the importance of considering individual patient factors and medical history when interpreting CHA2DS2-VASc scores and making anticoagulation therapy decisions.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Fails to clarify whether the patient's hypertension is well-controlled or not, which may impact anticoagulation therapy decisions.",
    "axis": "context_awareness",
    "point": 2
  },
  {
    "criterion": "Uses clear and concise language to explain the CHA2DS2-VASc score and its role in stroke risk assessment.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not provide specific guidance on how to manage the patient's anticoagulation therapy, such as the need for regular monitoring and dose adjustments.",
    "axis": "instruction_following",
    "point": -5
  },
  {
    "criterion": "Does not discuss the potential risks and benefits of anticoagulation therapy, including the risk of bleeding.",
    "axis": "completeness",
    "point": 3
  },
  {
    "criterion": "Provides incorrect information about the recommended duration of anticoagulation therapy for patients with atrial fibrillation and hypertension.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Does not consider alternative anticoagulation options, such as direct oral anticoagulants (DOACs), for patients with atrial fibrillation and hypertension.",
    "axis": "completeness",
    "point": 2
  },
  {
    "criterion": "Fails to address the potential impact of patient-specific factors, such as age, sex, and kidney function, on anticoagulation therapy decisions.",
    "axis": "context_awareness",
    "point": 1
  }
]